Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer

Update Il y a 4 ans
Reference: NCT01485874

Woman Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The purpose of this trial is to determine whether BIBF 1120 can be safely combined with pegylated liposomal doxorubicin (phase I), and to determine the clinical activity of the combination in patients with platinum-resistant ovarian cancer (phase II).


Inclusion criteria

  • Ovarian Cancer

Links